Last €132.00 EUR
Change Today +0.38 / 0.29%
Volume 892.0K
BAYN On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
BrsaItaliana
Xetra
Mexico
Continuous
As of 10:14 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-reg (BAYN) Snapshot

Open
€131.95
Previous Close
€131.62
Day High
€132.85
Day Low
€131.25
52 Week High
02/27/15 - €133.15
52 Week Low
04/15/14 - €89.49
Market Cap
109.2B
Average Volume 10 Days
2.1M
EPS TTM
€4.56
Shares Outstanding
826.9M
EX-Date
05/28/15
P/E TM
29.0x
Dividend
€2.25
Dividend Yield
1.59%
Current Stock Chart for BAYER AG-REG (BAYN)

bayer ag-reg (BAYN) Related Bloomberg News

View More Bloomberg News

bayer ag-reg (BAYN) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as anticoagulants; medicines to treat hemophilia, multiple sclerosis, cancer, eye diseases, pulmonary hypertension, high blood pressure, and infectious diseases; and contraceptives, as well as provides consumer health products, including over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; and contrast agent injection systems for diagnostic and therapeutic medical procedures in X-ray, computed tomography, and magnetic resonance imaging. The CropScience segment offers products in the areas of seeds and plant traits, and crop protection; and products for use in gardens and non-agricultural pest control, as well as green industry. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and specialty chemicals; and selected inorganic basic chemicals. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Founded in 1863

bayer ag-reg (BAYN) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €520.0K
Chief Strategy & Portfolio Officer and Member...
Total Annual Compensation: €2.0M
Labor Director and Member of Management Board
Total Annual Compensation: €1.6M
Member of Management Board, Chief Medical Off...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

bayer ag-reg (BAYN) Key Developments

Bayer AG Reports Group Earnings Results for the Fourth Quarter and Full Year of 2014; Provides Earnings Guidance for the Full Year of 2015

Bayer AG reported group earnings results for the fourth quarter and full year of 2014. For the quarter, the company reported its net profit plunged 50.8% to EUR 224 million (USD 254.5 million) due to higher research and development and selling costs. Earnings before interest and tax (EBIT) in the last quarter dropped 14.4% to EUR 561 million. At the same time, sales in the reporting period climbed by 11.6% to EUR 11 billion, fuelled by strong performance throughout the company’s three divisions. Adjusted EBITDA of EUR 1.8 billion was 4% above the previous year mainly due to higher volumes within all subgroups. Earnings were diminished by higher expenses for marketing and sales as well as research and development. Core earnings per share in the quarter were increased by 8% to EUR 1.19. For the full year, the company’s net profit jumped by 7.4% to EUR 3.4 billion. The company was able to achieve all targets for the full year, with sales growing by 7% to EUR 42 billion, in line with its raised guidance. The company delivered on its earnings promise, with adjusted EBITDA rising 5% despite a negative EUR 400 million currency effect. The company met it’s mid- to high single-digit percentage guidance on core EPS, achieving 7% growth in 2014. This success was, in particular, driven by the strong top line performance in Pharma and CropScience, both up 11%, and then the business expansion of Consumer Care. EBIT advances by 11.6% to EUR 5,506 million. EBITDA before special items up by 4.9% to EUR 8,812 million. Core earnings per share up 7.3% to EUR 6.02. The company provided earnings guidance for the full year of 2015. Looking ahead, the company said it is very optimistic about 2015 and expects full-year sales to grow in the low single-digit percentage range to EUR 46 billion. The result should be helped by positive currency effects of around 3%. Earnings before interest, tax, depreciation and amortization (EBITDA) before special items are projected to grow in the low to mid double-digit percentage range. However, the company also expects charges of around EUR 700 million on the integration of the acquired consumer care businesses and the floatation of the MaterialScience unit. The company expects core earnings per share in the low-teens percentage range. The guidance on the tax rate for 2015 is, again, 25%.

Bayer Proposes Dividend Hike for 2014

Bayer AG announced it would propose a dividend hike to EUR 2.25 (USD 2.55) per share for 2014 from EUR 2.10 apiece distributed for the previous year.

Bayer Reportedly In Talks To Sell Diabetes Devices Division To Panasonic

Bayer AG (DB:BAYN) in talks to sell its diabetes devices division but a sale is not imminent, two sources with knowledge of the matter told Reuters. Bayer is making a second attempt to sell the Contour blood glucose-meter business. Panasonic Healthcare Co., Ltd. has been in talks with Bayer over the diabetes devices division for some time, but final bids are some weeks off, one source with direct knowledge of the matter said. Bloomberg reported that a sale to Panasonic, which could be valued at between €1 billion and €2 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYN:GR €132.00 EUR +0.38

BAYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.33 USD -0.1728
Celgene Corp $121.58 USD +0.0514
Gilead Sciences Inc $103.38 USD -0.15
Sanofi €86.37 EUR -1.33
Siemens AG €98.68 EUR -0.74
View Industry Companies
 

Industry Analysis

BAYN

Industry Average

Valuation BAYN Industry Range
Price/Earnings 29.5x
Price/Sales 2.4x
Price/Book 5.0x
Price/Cash Flow 29.5x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-REG, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.